REPLIGEN CORP Additional Paid in Capital, Common Stock
REPLIGEN CORP (RGEN) had Additional Paid in Capital, Common Stock of $1.66 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-29
- 2026-06-30: Additional Paid in Capital, Common Stock $1.66B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.65B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.65B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.64B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.66B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $1.65B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.65B 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $1.64B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.63B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.62B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $1.62B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.61B 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $1.59B 10-Q/A · filed 2024-11-18 | $1.59B 10-Q · filed 2024-07-30 |
| 2024-03-31 | $1.57B 10-Q/A · filed 2024-11-18 | |
| 2023-12-31 | $1.57B 10-K · filed 2025-03-14 | |
| 2023-09-30 | $1.57B 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $1.56B 10-Q/A · filed 2024-11-18 | |
| 2023-03-31 | $1.54B 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $1.55B 10-Q/A · filed 2024-11-18 | |
| 2022-09-30 | $1.54B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $1.53B 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $1.53B 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $1.57B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $1.56B 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $1.48B 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $1.47B 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $1.46B 10-K · filed 2022-02-17 | |
| 2020-09-30 | $1.09B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.08B 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $1.07B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.07B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $1.06B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $892.96M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $645.88M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $642.59M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $639.03M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $635.36M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $631.60M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $628.98M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $626.77M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $247.63M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $245.96M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $242.04M 10-K · filed 2018-02-22 | |
| 2016-09-30 | $240.57M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $238.62M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $205.14M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $202.53M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $201.66M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $200.44M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $199.20M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $198.06M 10-K · filed 2016-02-25 | $198.06M 10-K · filed 2015-03-17 |
| 2013-12-31 | $190.63M 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |